2024
Cost-effectiveness and health impact of screening and treatment of Mycobacterium tuberculosis infection among formerly incarcerated individuals in Brazil: a Markov modelling study
van Lieshout Titan A, Klaassen F, Pelissari D, de Barros Silva J, Alves K, Alves L, Sanchez M, Bartholomay P, Johansen F, Croda J, Andrews J, Castro M, Cohen T, Vuik C, Menzies N. Cost-effectiveness and health impact of screening and treatment of Mycobacterium tuberculosis infection among formerly incarcerated individuals in Brazil: a Markov modelling study. The Lancet Global Health 2024, 12: e1446-e1455. PMID: 39151980, PMCID: PMC11339731, DOI: 10.1016/s2214-109x(24)00221-3.Peer-Reviewed Original ResearchConceptsDisability-adjusted life yearsTuberculosis preventive treatmentTuberculosis deathsHealth impactsImpact of screeningIntervention cost-effectivenessInfection screeningCost-effectiveNational Institutes of HealthHealth outcomesHealth gainsInstitutes of HealthQuantify health effectsTuberculosis casesCost-effectiveness ratioTreatment of Mycobacterium tuberculosis infectionPotential health impactsLife yearsGreater health benefitsTuberculosis preventionTarget populationMonths of isoniazidMarkov modelling studiesHealth statesHealth
2022
Re-evaluating the health impact and cost-effectiveness of tuberculosis preventive treatment for modern HIV cohorts on antiretroviral therapy: a modelling analysis using data from Tanzania
Zhu J, Lyatuu G, Sudfeld CR, Kiravu A, Sando D, Machumi L, Minde J, Chisonjela F, Cohen T, Menzies NA. Re-evaluating the health impact and cost-effectiveness of tuberculosis preventive treatment for modern HIV cohorts on antiretroviral therapy: a modelling analysis using data from Tanzania. The Lancet Global Health 2022, 10: e1646-e1654. PMID: 36240830, PMCID: PMC9553191, DOI: 10.1016/s2214-109x(22)00372-2.Peer-Reviewed Original ResearchMeSH KeywordsAntitubercular AgentsCD4 Lymphocyte CountCost-Benefit AnalysisHIV InfectionsHumansIsoniazidTanzaniaTuberculosisConceptsIsoniazid preventive therapyCD4 cell countAntiretroviral therapyCell countART cohortAverage CD4 cell countHigher CD4 cell countsLarge HIV treatment programHealth impactsTuberculosis preventive treatmentHIV treatment programsLifetime costsIncremental lifetime costLifetime health benefitsCourse of infectionGreater health gainsLong-term healthART initiationTreat guidelinesHIV cohortPreventive therapyTuberculosis riskUS National InstitutesHIV programsSubgroup analysis
2021
Adaptive Policies to Balance Health Benefits and Economic Costs of Physical Distancing Interventions during the COVID-19 Pandemic
Yaesoubi R, Havumaki J, Chitwood MH, Menzies NA, Gonsalves G, Salomon JA, Paltiel AD, Cohen T. Adaptive Policies to Balance Health Benefits and Economic Costs of Physical Distancing Interventions during the COVID-19 Pandemic. Medical Decision Making 2021, 41: 386-392. PMID: 33504258, PMCID: PMC8084913, DOI: 10.1177/0272989x21990371.Peer-Reviewed Original ResearchConceptsAdaptive policiesClear decision rulesSocial costsEconomic costsPolicy makersPhysical distancing policiesDecision toolPolicyPhysical distancing interventionsDistancing policiesModel-based experimentsDecision rulesReal-time surveillance dataCostCOVID-19 pandemicMakersShorter overall durationMore complex modelsHealth benefitsComplex modelsPandemicCurrent pandemicCOVID-19BenefitsRules
2020
Cost-effectiveness of post-treatment follow-up examinations and secondary prevention of tuberculosis in a high-incidence setting: a model-based analysis
Marx FM, Cohen T, Menzies NA, Salomon JA, Theron G, Yaesoubi R. Cost-effectiveness of post-treatment follow-up examinations and secondary prevention of tuberculosis in a high-incidence setting: a model-based analysis. The Lancet Global Health 2020, 8: e1223-e1233. PMID: 32827484, PMCID: PMC7549318, DOI: 10.1016/s2214-109x(20)30227-8.Peer-Reviewed Original ResearchMeSH KeywordsAftercareCost-Benefit AnalysisHumansIncidenceModels, TheoreticalSecondary PreventionSouth AfricaTuberculosisConceptsIsoniazid preventive therapySecondary preventive therapyHigh-incidence settingsPost-treatment followPreventive therapyTuberculosis controlTuberculosis incidenceTreatment completionTuberculosis case findingOverall disease burdenHigh tuberculosis incidenceTuberculosis-endemic settingHigh-incidence communityFirst yearHealth system costsRecurrent tuberculosisSecondary preventionAnnual followTuberculosis treatmentDisease burdenHigh riskCase findingSingle followSuburban Cape TownPreventive interventions
2019
Cost‐effectiveness of expanding the capacity of opioid agonist treatment in Ukraine: dynamic modeling analysis
Morozova O, Crawford FW, Cohen T, Paltiel AD, Altice FL. Cost‐effectiveness of expanding the capacity of opioid agonist treatment in Ukraine: dynamic modeling analysis. Addiction 2019, 115: 437-450. PMID: 31478285, PMCID: PMC7015766, DOI: 10.1111/add.14797.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentOpioid use disorderOAT coverageAgonist treatmentGross domestic productOpioid use initiationOpioid addiction epidemicOAT accessHIV epidemicUse disordersAddiction epidemicCapita gross domestic productPay thresholdsTreatment demandUse initiationAddiction treatmentIncremental costBaseline capacityTreatmentPotential peer effectsDomestic productTreatment spilloversEpidemicPeer effectsCoverage levelsCost-Effectiveness of Alternative Uses of Polyvalent Meningococcal Vaccines in Niger: An Agent-Based Transmission Modeling Study
Arifin SMN, Zimmer C, Trotter C, Colombini A, Sidikou F, LaForce FM, Cohen T, Yaesoubi R. Cost-Effectiveness of Alternative Uses of Polyvalent Meningococcal Vaccines in Niger: An Agent-Based Transmission Modeling Study. Medical Decision Making 2019, 39: 553-567. PMID: 31268405, PMCID: PMC6786941, DOI: 10.1177/0272989x19859899.Peer-Reviewed Original ResearchConceptsReactive campaignsSerogroup replacementConjugate vaccineOne-time catchPolyvalent meningococcal vaccineRoutine infant vaccinationMeningococcal conjugate vaccineMeningococcal polysaccharide vaccineRoutine infant immunizationCurrent vaccination practicesImportant health benefitsCost-effectiveness thresholdStandard cost-effectiveness thresholdsAgent-based transmission modelVaccination seriesImmunization seriesInfant vaccinationInfant immunizationPolysaccharide vaccineMeningococcal vaccineVaccination practicesPolyvalent vaccineLaboratory confirmationMenAfriVacSerogroups A
2018
The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study
Yaesoubi R, Trotter C, Colijn C, Yaesoubi M, Colombini A, Resch S, Kristiansen PA, LaForce FM, Cohen T. The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study. PLOS Medicine 2018, 15: e1002495. PMID: 29364884, PMCID: PMC5783340, DOI: 10.1371/journal.pmed.1002495.Peer-Reviewed Original ResearchMeSH KeywordsBurkina FasoCost-Benefit AnalysisHealth PolicyImmunization ProgramsMeningococcal VaccinesModels, TheoreticalVaccinationVaccines, ConjugateConceptsDisability-adjusted life yearsMeningococcal casesConjugate vaccineMeningitis beltVaccination strategiesMeningococcal serogroupsStrain replacementNationwide immunization campaignPolyvalent meningococcal vaccineMeningococcal conjugate vaccineCurrent World Health OrganizationAfrican meningitis beltAlternative vaccination strategiesAlternative vaccination policiesWorld Health OrganizationMeningococcal transmissionReactive campaignsMeningococcal vaccineImmunization campaignVaccination policyPolyvalent vaccineMeningitis epidemicsReactive vaccinationVaccine policyVaccine price
2016
Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models
Menzies NA, Gomez GB, Bozzani F, Chatterjee S, Foster N, Baena IG, Laurence YV, Qiang S, Siroka A, Sweeney S, Verguet S, Arinaminpathy N, Azman AS, Bendavid E, Chang ST, Cohen T, Denholm JT, Dowdy DW, Eckhoff PA, Goldhaber-Fiebert JD, Handel A, Huynh GH, Lalli M, Lin HH, Mandal S, McBryde ES, Pandey S, Salomon JA, Suen SC, Sumner T, Trauer JM, Wagner BG, Whalen CC, Wu CY, Boccia D, Chadha VK, Charalambous S, Chin DP, Churchyard G, Daniels C, Dewan P, Ditiu L, Eaton JW, Grant AD, Hippner P, Hosseini M, Mametja D, Pretorius C, Pillay Y, Rade K, Sahu S, Wang L, Houben RMGJ, Kimerling ME, White RG, Vassall A. Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models. The Lancet Global Health 2016, 4: e816-e826. PMID: 27720689, PMCID: PMC5527122, DOI: 10.1016/s2214-109x(16)30265-0.Peer-Reviewed Original ResearchMeSH KeywordsChinaCost-Benefit AnalysisDelivery of Health CareForecastingGoalsHealth Care CostsHealth ExpendituresHealth PolicyHealth ResourcesHealth Services AccessibilityHealth Services Needs and DemandHumansIndiaModels, TheoreticalPatient Acceptance of Health CareQuality-Adjusted Life YearsSouth AfricaTuberculosisConceptsPatient-incurred costsTuberculosis servicesConventional cost-effectiveness thresholdsHigh-burden countriesEnd TB StrategySubstantial health gainsNet cost savingsResource implicationsCost-effectiveness thresholdMost intervention approachesTB StrategyTuberculosis incidenceMost interventionsSocietal perspectiveHealth gainsIntervention mixMelinda Gates FoundationSubstantial healthHealth effectsCurrent practiceExpansion of accessIntervention approachesEmpirical cost dataCost dataInterventionIdentifying cost‐effective dynamic policies to control epidemics
Yaesoubi R, Cohen T. Identifying cost‐effective dynamic policies to control epidemics. Statistics In Medicine 2016, 35: 5189-5209. PMID: 27449759, PMCID: PMC5096998, DOI: 10.1002/sim.7047.Peer-Reviewed Original ResearchMeSH KeywordsCost-Benefit AnalysisDecision Support TechniquesEpidemicsHealth PolicyHumansInfluenza, HumanModels, TheoreticalVaccinationConceptsNet health benefitHighest net health benefitHealth benefitsTransmission-reducing interventionsDynamic policiesNovel viral pathogensCurrent interventionsHealth policyMathematical decision modelViral pathogensMonetary outcomesPolicy makersInterventionPolicyDecision modelStatic policyEpidemicEpidemic dataVaccinationVaccinePerformance measures
2015
The prospective evaluation of the TB strain typing service in England: a mixed methods study
Mears J, Vynnycky E, Lord J, Borgdorff MW, Cohen T, Crisp D, Innes JA, Lilley M, Maguire H, McHugh TD, Woltmann G, Abubakar I, Sonnenberg P. The prospective evaluation of the TB strain typing service in England: a mixed methods study. Thorax 2015, 71: thoraxjnl-2014-206480. PMID: 25882538, DOI: 10.1136/thoraxjnl-2014-206480.Peer-Reviewed Original ResearchConceptsDiagnostic delayTB incidenceTB notification ratesProportion of infectionsMycobacterium tuberculosis diagnosisFalse-positive diagnosesCost-effectiveness analysisMixed-methods evaluationStrain typingTB programsProspective evaluationNotification ratesInfection increasesTuberculosis diagnosisPositive diagnosisPublic health dataComplex interventionsIncidenceMixed-methods studyRoutine laboratoryDiagnosisHealth dataCluster investigationsTypingMethods study
2014
Modeling of Novel Diagnostic Strategies for Active Tuberculosis – A Systematic Review: Current Practices and Recommendations
Zwerling A, White RG, Vassall A, Cohen T, Dowdy DW, Houben RM. Modeling of Novel Diagnostic Strategies for Active Tuberculosis – A Systematic Review: Current Practices and Recommendations. PLOS ONE 2014, 9: e110558. PMID: 25340701, PMCID: PMC4207742, DOI: 10.1371/journal.pone.0110558.Peer-Reviewed Original ResearchConceptsNucleic acid amplification testsIncremental cost-effectiveness ratioActive tuberculosisHealth system modelDiagnostic strategiesNovel diagnostic strategiesAlternative nucleic acid amplification testsXpert MTB/RIFMTB/RIFCost-effectiveness ratioMulti-way sensitivity analysesFalse-negative diagnosesPre-diagnostic periodCost-effectiveness modelCost-effectiveness estimatesDiagnostic delayDiagnostic pathwayAdditional epidemiological dataTB diagnosticsEpidemiological dataReference listsAmplification testsEpidemiological impactEligible papersEpidemiological settingsProspective evaluation of a complex public health intervention: lessons from an initial and follow-up cross-sectional survey of the tuberculosis strain typing service in England
Mears J, Abubakar I, Crisp D, Maguire H, Innes JA, Lilley M, Lord J, Cohen T, Borgdorff MW, Vynnycky E, McHugh TD, Sonnenberg P. Prospective evaluation of a complex public health intervention: lessons from an initial and follow-up cross-sectional survey of the tuberculosis strain typing service in England. BMC Public Health 2014, 14: 1023. PMID: 25273511, PMCID: PMC4194411, DOI: 10.1186/1471-2458-14-1023.Peer-Reviewed Original ResearchMeSH KeywordsAttitude of Health PersonnelBacterial Typing TechniquesClinical CompetenceCost-Benefit AnalysisCross-Sectional StudiesEnglandFemaleFollow-Up StudiesHealth ServicesHumansMaleMolecular EpidemiologyMycobacteriumPopulation SurveillanceProgram EvaluationProspective StudiesPublic HealthSurveys and QuestionnairesTuberculosisConceptsPublic health interventionsComplex public health interventionsCross-sectional surveyHealth interventionsNational public health interventionsStrain typingPublic health staffRepeated cross-sectional surveySignificant increaseMIRU-VNTR typingProportion of respondentsTB patientsSelf-rated knowledgeTB controlProspective evaluationMixed-method evaluationHealth staffProspective identificationMajority of respondentsService users' perceptionsMethodsAn onlineInterventionTypingFuture evaluationProfessional groupsAssessment of the patient, health system, and population effects of Xpert MTB/RIF and alternative diagnostics for tuberculosis in Tanzania: an integrated modelling approach
Langley I, Lin HH, Egwaga S, Doulla B, Ku CC, Murray M, Cohen T, Squire SB. Assessment of the patient, health system, and population effects of Xpert MTB/RIF and alternative diagnostics for tuberculosis in Tanzania: an integrated modelling approach. The Lancet Global Health 2014, 2: e581-e591. PMID: 25304634, DOI: 10.1016/s2214-109x(14)70291-8.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioHigh incremental costIncremental costLED fluorescence microscopyCost-effectiveness ratioPay thresholdsFull rolloutContext of TanzaniaCost-effective optionHealth policy formulationPolicy formulationDifferent diagnostic optionsIntegrated modelling approachModelling approachAdditional costHealth systemCostAlternative diagnosticsIntegrated modelXpert MTB/RIFPopulation effectsMTB/RIFPresumptive tuberculosis casesWillingnessUse of XpertImpact and cost-effectiveness of current and future tuberculosis diagnostics: the contribution of modelling
Dowdy DW, Houben R, Cohen T, Pai M, Cobelens F, Vassall A, Menzies NA, Gomez GB, Langley I, Squire SB, White R, for the TB MAC meeting participants. Impact and cost-effectiveness of current and future tuberculosis diagnostics: the contribution of modelling. The International Journal Of Tuberculosis And Lung Disease 2014, 18: 1012-1018. PMID: 25189546, PMCID: PMC4436823, DOI: 10.5588/ijtld.13.0851.Peer-Reviewed Original Research
2013
Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, Hontelez JA, Humair S, Kerr CC, Klein DJ, Mishra S, Mitchell KM, Nichols BE, Vickerman P, Bakker R, Bärnighausen T, Bershteyn A, Bloom DE, Boily MC, Chang ST, Cohen T, Dodd PJ, Fraser C, Gopalappa C, Lundgren J, Martin NK, Mikkelsen E, Mountain E, Pham QD, Pickles M, Phillips A, Platt L, Pretorius C, Prudden HJ, Salomon JA, van de Vijver DA, de Vlas SJ, Wagner BG, White RG, Wilson DP, Zhang L, Blandford J, Meyer-Rath G, Remme M, Revill P, Sangrujee N, Terris-Prestholt F, Doherty M, Shaffer N, Easterbrook PJ, Hirnschall G, Hallett TB. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. The Lancet Global Health 2013, 2: e23-34. PMID: 25104632, DOI: 10.1016/s2214-109x(13)70172-4.Peer-Reviewed Original ResearchConceptsHIV-positive adultsAdult antiretroviral therapyAntiretroviral therapyCD4 countTreatment coveragePotential health benefitsConcentrated epidemicsDALY avertedHealth benefitsEligibility criteriaExpansion of eligibilityEarlier eligibilityCD4 count thresholdHealth system perspectiveHead gross domestic productMiddle-income settingsGeneral populationHealth outcomesKey populationsTherapyHealth interventionsHealth budgetIncremental costMelinda Gates FoundationEligibility
2012
Population Health Impact and Cost-Effectiveness of Tuberculosis Diagnosis with Xpert MTB/RIF: A Dynamic Simulation and Economic Evaluation
Menzies NA, Cohen T, Lin HH, Murray M, Salomon JA. Population Health Impact and Cost-Effectiveness of Tuberculosis Diagnosis with Xpert MTB/RIF: A Dynamic Simulation and Economic Evaluation. PLOS Medicine 2012, 9: e1001347. PMID: 23185139, PMCID: PMC3502465, DOI: 10.1371/journal.pmed.1001347.Peer-Reviewed Original ResearchConceptsMultidrug-resistant TBCost-effectiveness ratioInitial diagnosisXpert MTB/RIF testMTB/RIF testXpert MTB/RIFIntroduction of XpertTB natural historyTB-HIV coinfectionMultidrug-resistant tuberculosisHigh HIV prevalenceMTB/RIFHealth system costsImplementation of XpertHealth impactsPopulation health impactCost-effectiveness resultsLong-term transmission dynamicsWorld Health OrganizationAntiretroviral therapyTB casesTB deathsTB morbidityHIV prevalenceRIF test